Manish Anandani to succeed Prabha Narasimhan as Colgate-Palmolive India MD-CEO

Former Kenvue India MD Manish Anandani will take over as managing director and CEO of Colgate-Palmolive India on September 28, 2026. Prabha Narasimhan’s tenure ends a day earlier as she moves to an Asia-Pacific marketing role.

— Source published Fri, 21 Aug, 2026, 09:35 IST · First seen Fri, 21 Aug, 2026, 09:42 IST · Source Mint

What happened

Colgate-Palmolive (India) · Colgate-Palmolive India MD-CEO Prabha Narasimhan will resign effective September 27, 2026, following her promotion to an

Key facts

  • Prabha Narasimhan's tenure ends September 27, 2026
  • Manish Anandani assumes MD and CEO role September 28, 2026
  • Anandani's appointment is for five consecutive years
  • He previously worked at Colgate-Palmolive from 2005 to 2018

Why this matters

Anandani’s Kenvue background may broaden Colgate-Palmolive India’s perspective on consumer-health partnerships and portfolio adjacencies, though the announcement signals succession rather than an immediate transaction catalyst.

What to watch

  • Whether Anandani retains the current India commercial, marketing and finance leadership or appoints external executives.
  • Changes in advertising intensity, promotional depth and retailer margins versus the two quarters preceding the handover.
  • New launches or renovations in sensitivity, gum health, whitening, toothbrush and mouthwash categories.
  • Growth in e-commerce, quick-commerce, pharmacy and modern-trade contribution relative to general trade.
  • Any revised medium-term guidance on volume growth, gross margin, premium mix or market-share targets.
  • Competitor responses, especially price packs, trade schemes and oral-care advertising from HUL, Dabur and Patanjali.
  • Announce the incoming CEO's strategic priorities, leadership-team changes and mandate for the India business before or shortly after the September 2026 transition.
  • Review marketing and trade-spend allocation across mass, premium, sensitivity and toothbrush segments.
  • Increase emphasis on pharmacy, dental-professional, quick-commerce and e-commerce channels if consumer-health adjacency becomes a priority.
  • Launch or scale clinically positioned oral-care innovations and bundled oral-health routines.
  • Reassure distributors, key modern-trade accounts and employees that core route-to-market and supply-chain programs will continue through the transition.

Also reported by